Sydney, February 16, 2026, 17:01 AEDT — Market closed
- CSL shares closed up 1.4% after the company flagged Australian approval for its neffy adrenaline nasal spray
- A buyback update showed CSL kept repurchasing shares, following last week’s sharp slide
CSL Ltd shares closed 1.4% higher on Monday, trimming some of last week’s losses, after the company said its Seqirus unit’s neffy adrenaline nasal spray had been approved for use in Australia and updated the market on its ongoing share buyback. The stock ended at A$152.17, but is still down about 15.6% over the past five sessions. (MarketScreener)
The move matters because CSL’s share price has been under pressure and investors have been hunting for anything concrete — new products, tighter costs, capital returns — that can steady sentiment. Monday’s lift was modest, but it came with fresh, company-specific headlines rather than broad market noise.
CSL Seqirus said neffy (adrenaline/epinephrine) nasal spray is now available and approved in Australia for emergency treatment of anaphylaxis — a severe allergic reaction — in adults and children aged four and over who weigh at least 15 kg. “The approval of neffy is very welcome,” said Professor Connie Katelaris, a NSW allergist, calling it the first new way of administering adrenaline approved in Australia in more than 30 years. Allergy & Anaphylaxis Australia’s Maria Said said an option that “does not require injection” could help patients and clinicians choose the device that best fits their needs. CSL Seqirus executive medical director Dr Jonathan Anderson said CSL had applied for Pharmaceutical Benefits Scheme funding, with the submission to be considered in March 2026. (Global Newsroom | CSL)
Separately, a filing showed CSL continued its on-market buyback, repurchasing 126,464 shares on the previous trading day for about A$19.2 million, with the day’s prices ranging from A$150.01 to A$156.11. The company said the buyback program runs to June 30, 2026, and is intended to total up to US$750 million, with UBS Securities Australia acting as broker. (CSL Limited)
An on-market buyback means the company purchases its own shares on the stock exchange, shrinking the share count over time and potentially supporting earnings per share. It can also signal that management sees value at current levels, though it does not set a floor under the price.
Still, the near-term commercial impact of neffy is unclear. Uptake will depend on prescribing, patient preference and reimbursement, and the PBS process can be lengthy and uncertain.
The next clear milestone is March, when CSL said its PBS submission for neffy will be considered — a decision investors will watch for clues on pricing and access, alongside further buyback updates. (Global Newsroom | CSL)
